Literature DB >> 15350518

Antibody zymography: a novel adaptation of zymography to determine the protease-neutralising potential of specific antibodies and snake antivenoms.

S S Hasson1, R D G Theakston, R A Harrison.   

Abstract

A common problem in the development of antibody-based therapeutics is the selection, usually from a large population, of specific antibodies with the desired function. One of our research objectives is to identify antibodies capable of neutralising the most important haemorrhagic and haemostasis-disruptive proteases from viper venom. Here, we describe a modification of conventional gelatin-zymography that permits the identification of antibodies capable of neutralising gelatinolytic proteases. We demonstrate that the gelatinolytic activity of viper venom proteases is neutralised by addition of viper antivenom to the matrix of conventional gelatin-zymograms. Venom protein gelatinolytic activity was unaffected by inclusion of antibody from control, non-immunised animals or immunoglobulin-depleted serum. The application of this antibody zymogram technique for future research on snake venoms is evaluated in the context of identified limitations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350518     DOI: 10.1016/j.jim.2004.06.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

Review 1.  Zymography methods for visualizing hydrolytic enzymes.

Authors:  Jennifer Vandooren; Nathalie Geurts; Erik Martens; Philippe E Van den Steen; Ghislain Opdenakker
Journal:  Nat Methods       Date:  2013-03       Impact factor: 28.547

2.  Antisnake Venom Activity of Hibiscus aethiopicus L. against Echis ocellatus and Naja n. nigricollis.

Authors:  S S Hasson; A A Al-Jabri; T A Sallam; M S Al-Balushi; R A A Mothana
Journal:  J Toxicol       Date:  2010-06-06

3.  Enzymatic Analysis of Iranian Echis carinatus Venom Using Zymography.

Authors:  Mostafa Kamyab; Euikyung Kim; Seyed Mehdi Hoseiny; Ramin Seyedian
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.